Complications of Age-Related Macular Degeneration Prevention Trial
Launched by NATIONAL EYE INSTITUTE (NEI) · Sep 23, 1999
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
Complications of age-related macular degeneration (AMD) are the leading cause of severe vision loss among people aged 65 and over in the United States and many Western countries. Most, (approximately 90 percent), of this vision loss is due to the neovascular (or wet) form of AMD. The word neovascular describes the development of new, abnormal blood vessels in the back of the eye. Unfortunately, the majority of these new vessels are not amenable to currently available treatments.
The first sign that an eye may develop AMD is the presence of drusen, yellowish deposits under the retina. Curre...
Gender
ALL
Eligibility criteria
- Patients eligible for CAPT can be either male or female and meet the following criteria:
- • Age at least 50 years old
- • Vision in each eye must measure 20/40 or better.
- • At least 10 large drusen in each eye
- • Available for follow-up examinations for 5 years after enrollment
- • Final eligibility is determined through a detailed eye examination by a CAPT-certified ophthalmologist.
About National Eye Institute (Nei)
The National Eye Institute (NEI), part of the U.S. National Institutes of Health (NIH), is dedicated to conducting and supporting innovative research to understand, prevent, and treat eye diseases and vision disorders. As a leading sponsor of clinical trials, NEI aims to advance knowledge in ocular health through rigorous scientific inquiry and collaboration with researchers, healthcare professionals, and institutions. By fostering the development of new therapies and technologies, NEI plays a pivotal role in enhancing the quality of life for individuals affected by visual impairments and eye conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Atlanta, Georgia, United States
Iowa City, Iowa, United States
Mesa, Arizona, United States
Peoria, Arizona, United States
San Francisco, California, United States
Tampa, Florida, United States
Chicago, Illinois, United States
Harvey, Illinois, United States
Louisville, Kentucky, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Royal Oak, Michigan, United States
St. Louis, Missouri, United States
Edison, New Jersey, United States
Lakewood, New Jersey, United States
Charlotte, North Carolina, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Portland, Oregon, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Dallas, Texas, United States
Madison, Wisconsin, United States
Patients applied
Trial Officials
Stuart L Fine, MD
Study Chair
Scheie Eye Institute, The University of Pennsylvania School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials